Trans-resveratrol oral - Jupiter Orphan Therapeutics

Drug Profile

Trans-resveratrol oral - Jupiter Orphan Therapeutics

Alternative Names: JOT 101; JOT 102; JOT 104; JOT 105; JOT 106; JOTROL

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jupiter Orphan Therapeutics
  • Developer Jupiter Orphan Therapeutics; Mayo Clinic; Murdoch Childrens Research Institute; Universidade de Coimbra
  • Class Antineoplastics; Antithrombotics; Cardiovascular therapies; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Friedreich's ataxia
  • Phase I Mucopolysaccharidosis I
  • Preclinical Pancreatic cancer; Spinocerebellar degeneration

Most Recent Events

  • 14 Mar 2018 Jupiter Orphan Therapeutics plans a pharmacokinetic, safety clinical trial in Mucopolysaccharidosis Type-I
  • 14 Mar 2018 Jupiter Orphan Therapeutics plans clinical trials in Friedreich's Ataxia and other mitochondrial dysfunction related diseases
  • 12 Mar 2018 Jupiter Orphan Therapeutics files an IND application with the US Food and Drug Administration in USA for Mucopolysaccharidosis Type-I
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top